newsfilter
← Latest News
GlobeNewswire·

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

SCNX
  • Scienture Holdings Inc. (NASDAQ: SCNX) has initiated commercial sales and fulfilled first customer orders for Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL.
  • Arbli™ is the first FDA-approved ready-to-use oral suspension of losartan potassium, eliminating the need for compounding.
  • The U.S. losartan market generates approximately $256 million in annual sales with over 71 million prescriptions annually based on IQVIA data.
  • Scienture has secured PBM-Led GPO agreements & finalized multiple commercial GPO contracts to expand access across 2,500+ healthcare institutions nationwide.
  • The product covers an estimated 20% of the U.S. institutional market including hospitals, clinics, nursing homes, long-term care facilities, & specialty pharmacies.
  • Arbli™ is indicated for hypertension treatment in patients over six years old, stroke risk reduction in patients with left ventricular hypertrophy, & diabetic nephropathy in type 2 diabetes.
  • The medication is available as a 165 mL peppermint-flavored suspension requiring no refrigeration with a 24-month shelf life at room temperature.
  • Safety warnings include contraindications for use during pregnancy, restrictions on co-administration with aliskiren for diabetic patients, & avoidance in severe hepatic impairment.
  • Common adverse reactions include dizziness, upper respiratory infection, nasal congestion, & back pain.
  • The product holds two issued USPTO patents listed in the FDA Orangebook.